DNTH news & sentiment — Dianthus Therapeutics, Inc. /DE/

MAY 1·The Manila TimesLow

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics granted equity awards to six new non-executive employees on May 1, 2026. These inducement grants, approved by the company's Compensation Committee, consist of non-qualified stock options for 135,000 shares of common stock with a 10-year term and an exercise price of $87.42 per share. The grants aim to attract new talent and are in accordance with Nasdaq Listing Rule 5635(c)(4).

APR 3·Moomoo

Dianthus Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

This article is a notice of the proposed sale of securities by Dianthus Therapeutics, filed pursuant to Rule 144. It is a mandatory disclosure related to the sale of restricted and control securities.

MAR 17·Meyka

William Blair Maintains Outperform on Dianthus Therapeutics (DNTH) March 2026

William Blair has reiterated its Outperform rating on Dianthus Therapeutics (DNTH) as of March 16, 2026, signaling continued confidence in the company's development pipeline and commercial prospects without issuing a new price target. This recommitment comes after Dianthus priced an upsized offering, raising approximately $625 million. Meyka AI rates DNTH with a B+ grade, highlighting important catalysts like planned clinical readouts and regulatory interactions.

$DNTH

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

William Blair Maintains Outperform on Dianthus Therapeutics (DNTH) March 2026

News on $DNTH